Oncology Data Advisor™ · Studying Olutasidenib in Relapsed/Refractory Acute Myeloid Leukemia With Jorge Cortes, MD At the recent American Society of Hematology (ASH) Annual Meeting in New Orleans, Jorge Cortes, Director of the Georgia Cancer Center in Augusta, Georgia, sat down with Oncology Data Advisor to discuss his presentation regarding the results of a pivotal phase 2 study in which olutasidenib was studied in patients with relapsed/refractory isocitrate dehydrogenase 1 (IDH1)...
Understanding the balance between effective treatments and health-related quality of life is crucial, especially when treating older adults with hematologic malignancies. The Cancer and Aging Research Group (CARG) chemotherapy toxicity calculator has been sufficiently studied and utilized in patients with solid tumors; however, its efficacy in the hematologic malignancy setting was previously unknown. In a study recently presented at the American Society of Hematology (ASH) 63rd Annual Meeting &...
For patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), less than half of patients are cured with the current standard of care, and effective treatments are greatly needed. In the phase 3 POLARIX trial, a team of researchers investigated the efficacy of polatuzumab vedotin in combination with R-CHP (rituximab/cyclophosphamide/doxorubicin/prednisone) for this population. In this interview, one of the study's investigators, Dr. John Burke of Rocky Mountain Cancer Centers and the U...
While the current standard of care for relapsed/refractory large B-cell lymphoma is high-dose therapy with autologous stem cell rescue, many patients do not respond to or cannot tolerate high-dose therapy. As a result, outcomes for second-line treatment remain poor. At the recent American Society of Hematology (ASH) 63rd Annual Meeting & Exposition in Atlanta, Georgia, Dr. Frederick Locke of Moffitt Cancer Center presented the primary results of ZUMA-7, a phase 3 clinical trial investigating...
Compared with the non-Hispanic White population, Hispanic and Black adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) experience significantly inferior outcomes. In an analysis of the CALGB 10403 AYA trial presented at the recent American Society of Hematology (ASH) 63rd Annual Meeting & Exposition in Atlanta, Georgia, a team of researchers led by Dr. Lori Muffly, Associate Professor of Medicine at Stanford University, investigated racial and ethnic disparities in cl...
For patients with relapsed/refractory large B-cell lymphoma (LBCL), treatment options are limited, and outcomes remain poor with the current standard of care. In the phase 3 TRANSFORM trial, Dr. Manali Kamdar, Clinical Director of Lymphoma Services at the University of Colorado Anschutz School of Medicine, and colleagues investigated the efficacy of lisocabtagene maraleucel (liso-cel), an anti-CD19–directed chimeric antigen receptor (CAR) T-cell therapy, in this setting. Dr. Kamdar recently pres...
For patients with extensive-stage small cell lung cancer (SCLC), cytotoxic chemotherapy remains a mainstay of treatment. However, myelosuppressive hematologic adverse events such as anemia, neutropenia, and thrombocytopenia pose a significant challenge to care. In a study recently presented at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia, a team of researchers led by Dr. Jerome Goldschmidt, medical oncologist at Blue Ridge Cancer Care and the ...
Although survival in childhood acute lymphoblastic leukemia (ALL) has improved over the years, there remains a need to identify racial, ethnic, and socioeconomic health disparities that contribute to poor outcomes. In a study recently presented at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition, a team of researchers led by Dr. Sumit Gupta of the University of Toronto investigated the impact of race, ethnicity, and socioeconomic status among young patients with ALL ...
Tumor suppressor gene p53 is the most frequently mutated gene in human malignancy. Through a complex series of molecular events, p53 leads to malignant cell proliferation and plays a significant role in tumor formation. In the Presidential Symposium at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia, Dr. Matthew Davids of Harvard Medical School discussed the current therapeutic strategies used to inhibit or reactivate mutant p53 in the treatment of hematologic malignancies. In this interview with Oncology Data Advisor, Dr. Davids delves further into the latest research in p53-directed therapeutic strategies and the future of targeting this specific mutation.
In the phase 3 BELINDA trial, a team of researchers led by Dr. Michael Bishop, Director of Hematopoietic Stem Cell Transplantation at the University of Chicago Medicine, investigated tisagenlecleucel (tisa-cel), a chimeric antigen receptor (CAR) T-cell therapy, as second-line treatment for patients with relapsed/refractory aggressive non-Hodgkin lymphoma. The investigators found that tisa-cel did not improve event-free survival compared with the standard of care, which consisted of platinum-based chemotherapy followed by autologous stem cell transplant in responders. Dr. Bishop recently presented the results of the trial at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia. In this interview with Oncology Data Advisor, he explains how these results should be interpreted and their significance for the future of CAR T-cell therapy.
Patients undergoing autologous stem cell transplant (ASCT) for multiple myeloma face significant challenges in quality of life, including anxiety, acute symptom burden, and decreased physical function. At the recent 63rd American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia, Dr. Rahul Banerjee and Dr. Kelly Brassil presented their research regarding digital life coaching for this patient population. In this interview with Oncology Data Advisor, Dr. Banerjee and Dr. Brassil discuss their results from a prior pilot study on this topic, the design of an ongoing phase 2 trial to continue the research, and its implications for improving the quality of life for patients undergoing ASCT for multiple myeloma.